About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
Roser Ferrer Costa
Zamira Vanessa Diaz Riascos
Joan López Hellin
Clara Carnicer Cáceres
Francisco Rodríguez Frias
David Tabernero Caellas
Funding agency: GILEAD SCIENCES SLU
Ibane Abasolo Olaortua
José Antonio Arranz Amo, Raquel Barquin Del Pino , Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Francisco Rodríguez Frias, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Francesc Martínez Trucharte, Pablo Gabriel Medina, Rosanna Paciucci Barzanti, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Beatriz Pacín Ruíz, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese
Funding agency: AGAUR no fer servir-correcte 4301-37
Reference: 2021 SGR 01173
Ibane Abasolo Olaortua
Diana Fernandes de Rafael, Miriam Izquierdo Sans
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Marta Martínez Vicente
José Antonio Arranz Amo, Eddie Pradas Gracia, Laura Castillo Ribelles, Clara Carnicer Cáceres, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Pablo Castillo Sánchez
Funding agency: Fundació "La Caixa"
The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.